Davern Capital Partners
Latest statistics and disclosures from Davern Capital Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PFE, REGN, INSM, IONS, NTRA, and represent 45.83% of Davern Capital Partners's stock portfolio.
- Added to shares of these 10 stocks: INSM (+$30M), LLY (+$17M), NTRA (+$13M), IONS (+$11M), GENB (+$7.4M), PRCT (+$6.5M), MLYS (+$6.4M), GPCR (+$6.1M), LEGN, ABVX.
- Started 4 new stock positions in INSM, GENB, PRCT, GPCR.
- Reduced shares in these 7 stocks: RPRX (-$15M), PFE (-$13M), CGON (-$6.7M), REGN (-$5.9M), BNTX (-$5.9M), ROIV, ARGX.
- Sold out of its position in CGON.
- Davern Capital Partners was a net buyer of stock by $56M.
- Davern Capital Partners has $365M in assets under management (AUM), dropping by 17.86%.
- Central Index Key (CIK): 0002003147
Tip: Access up to 7 years of quarterly data
Positions held by Davern Capital Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Davern Capital Partners
Davern Capital Partners holds 17 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Pfizer (PFE) | 12.3 | $45M | -21% | 1.6M | 28.08 |
|
| Regeneron Pharmaceuticals (REGN) | 9.5 | $35M | -14% | 45k | 772.64 |
|
| Insmed Com Par $.01 (INSM) | 8.2 | $30M | NEW | 183k | 163.52 |
|
| Ionis Pharmaceuticals (IONS) | 8.0 | $29M | +62% | 387k | 75.09 |
|
| Natera (NTRA) | 7.9 | $29M | +83% | 144k | 199.99 |
|
| Biontech Se Sponsored Ads (BNTX) | 7.4 | $27M | -17% | 305k | 88.88 |
|
| Argenx Se Sponsored Adr (ARGX) | 7.0 | $26M | 35k | 730.25 |
|
|
| Eli Lilly & Co. (LLY) | 6.9 | $25M | +228% | 27k | 919.77 |
|
| Royalty Pharma Shs Class A (RPRX) | 6.8 | $25M | -38% | 520k | 47.97 |
|
| Roivant Sciences SHS (ROIV) | 6.6 | $24M | -15% | 873k | 27.70 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 6.5 | $24M | +24% | 1.3M | 18.09 |
|
| Mineralys Therapeutics (MLYS) | 3.3 | $12M | +112% | 447k | 27.09 |
|
| Abivax Sa Sponsored Ads (ABVX) | 2.4 | $8.7M | +61% | 78k | 111.35 |
|
| Generate Biomedicines Com Shs (GENB) | 2.0 | $7.4M | NEW | 592k | 12.50 |
|
| Procept Biorobotics Corp (PRCT) | 1.8 | $6.5M | NEW | 261k | 25.01 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.7 | $6.1M | NEW | 127k | 48.20 |
|
| Miragen Therapeutics (VRDN) | 1.6 | $5.9M | +15% | 303k | 19.56 |
|
Past Filings by Davern Capital Partners
SEC 13F filings are viewable for Davern Capital Partners going back to 2025
- Davern Capital Partners 2026 Q1 filed May 14, 2026
- Davern Capital Partners 2025 Q4 filed Feb. 13, 2026